Vaccines | 新冠疫苗专刊投稿开启，欢迎各位专家同仁踊跃投稿
各位专家和同仁！
目前新冠疫苗专刊的投稿网络通道已经建好。具体投稿信息及要求，请用下面链接打开，提前了解。尽管最终的截止日期是明年，但现在就可以投稿，先投先送reviews，通过review的可接受并依次发表。谢谢支持！
投稿链接：https://www.mdpi.com/journal/vaccines/special_issues/vaccines_development
王宾 博士
Vaccines新冠疫苗专刊 特邀编委
投稿邮箱：bwang@advaccine.com
01Message from the Guest Editor
Dear Colleagues,
Although several vaccines have been approved for market fight against the COVID-19, we still face the breakthrough established host immunity or even serological mutations from its variants.
Aim: This special issuewill provide a platform for discussing potential novel strategies for better vaccine designs, research works, and experimental results against the COVID-19.
Scope:
Novel designs for COVID-19 vaccine, including broadening spectrum, sarbecovirus,multivalent, multi- or mosaic-antigens;
Multiple vaccine technological platforms;
Protectivemechanisms;
Correlation of protection and immune response.
Deadline for manuscript submissions:
29 April 2023
Dr. Bin Wang，Guest Editor
Shanghai MedicalCollege, Fudan University, Shanghai 200032, China
02Message from the Editor-in-Chief
Vaccines (ISSN 2076-393X) has had a 6-yearhistory of publishing peer-reviewed state of the artresearch that advances the knowledge of immunology inhuman disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of thehighlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud topresent the work and perspectives of many to contributeto future decisions concerning human health.
Prof. Dr. Ralph A. Tripp Editor in Chief
Department of Infectious Diseases, College of Veterinary Medicine,University of Georgia Athens, GA 30602-7387, USA
03Author Benefits
Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE(Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and many otherdatabases.
Journal Rank:JCR - Q2 (Immunology)
投稿链接：https://www.mdpi.com/journal/vaccines/special_issues/vaccines_development
推荐文章
尴尬的中国mRNA疫苗，还有好日子吗？
Nature Med余宏杰团队指明未来防疫方向
SAGE主席:我们还需要新疫苗吗？——写在智飞生物新冠疫苗三期临床试验数据发表后
